Organization (Government)
National Center for AIDS/STD Control and Prevention,China CDC
ClinicalTrials.gov lists National Center for AIDS/STD Control and Prevention,China CDC as lead sponsor of 11 trials. It has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers National Center for AIDS/STD Control and Prevention,China CDC: 11 lead-sponsored trials and 1 legal-entity registration. The parent company on record for National Center for AIDS/STD Control and Prevention,China CDC is Chinese Center For Disease Control and Prevention, which does not have its own page on this site.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (7)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| HIV Infections | 12 |
| Acquired Immunodeficiency Syndrome | 9 |
| Syphilis | 3 |
| Hepatitis C | 2 |
| Hepatitis B | 1 |
Showing 5 of 7 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 4 |
| 2011 | 2 |
| 2010 | 2 |
| 2009 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Regimen：BIC+FTC+TAF | 1 |
| Regimen:TDF+3TC+EFV | 1 |
Biomarker capability evidence (10)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ART4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| NOB1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 10 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Chinese Center For Disease Control and Prevention: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.